The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor

Nature Medicine

Volumn 7, Issue 5, 2001, Pages 569-574

  Basu, Sujit ^a   Nagy, Janice A ^a   Pal, Soumitro ^a   Vasile, Eliza ^a   Eckelhoefer, Isabelle A ^a   Bliss, V Susan ^a   Manseau, Eleanor J ^a   Dasgupta, Partha S ^a   Dvorak, Harold F ^a   Mukhopadhyay, Debabrata ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL MIGRATION; CELL PROLIFERATION; DOPAMINE METABOLISM; DRUG RECEPTOR BINDING; ENDOTHELIUM CELL; GROWTH INHIBITION; MEDIATOR RELEASE; MOUSE; NEUROTRANSMITTER RELEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; DOPAMINE; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MICE; MICE, INBRED C3H; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN ISOFORMS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035026748     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/87895     Document Type: Article

References (41)

1. Graybiel, A.M., Hirsch, E.C. & Agid, Y. The nigrostriatal system in Parkinson's disease. Adv. Neurol. 53, 17-29 (1990).
2. Goldstein, M. & Deutch, A.Y. Dopaminergic mechanisms in the pathogenesis of schizophrenia. FASEB J. 6, 2413-2421 (1992).
3. Olanow, C.W. & Tatton, W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22, 123-144 (1999).
4. Egan, M.F. & Weinberger, D.R. Neurobiology of schizophrenia. Curr. Opin. Neurobiol. 7, 701-707 (1997).
5. Wick, M.M. Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J. Invest. Dermatol. 71, 163-164 (1978).
6. Wick, M.M. 3, 4-Dihydroxybenzylamine: a dopamine analog with enhanced antitumor activity against B16 melanoma. J. Natl. Cancer Inst. 63, 1465-1467 (1979).
7. Wick, M.M. Levodopa and dopamine analogs: melanin precursors as antitumor agents in experimental human and murine leukemia. Cancer Treat. Rep. 63, 991-997 (1979).
8. Wick, M.M. Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res. 40, 1414-1418 (1980).
9. Wick, M.M. Levodopa and dopamine analogs: dihydroxy and trihydroxybenzy-lamines as novel quinol antitumor agents in experimental leukemia in vivo. Cancer Treat. Rep. 65, 861-867 (1981).
10. Wick, M.M. & Mui, A. Synthesis and biologic evaluation of the dopamine analog N-acetyldopamine in experimental leukemia in mice. J. Natl. Cancer Inst. 66, 351-354 (1981).
11. Dasgupta, P.S. & Lahiri, T. Antitumor effect of i.p. dopamine in mice bearing Ehrlich ascites carcinoma. J. Cancer Res. Clin. Oncol. 113, 363-368 (1987).
12. Basu, S. & Dasgupta, P.S. Role of dopamine in malignant tumor growth. Endocrine 12, 237-241 (2000).
13. Basu, S. & Dasgupta, P.S. Dopamine, a neurotransmitter, influences the immune system. J. Neuroimmunol. 102, 113-124 (2000).
14. Ricci, A., Collier, W.L. & Amenta, F. Pharmacological characterization and autoradiographic localization of dopamine receptors in the portal vein. J. Auton. Pharmacol. 14, 61-68 (1994).
15. Bacic, F., Uematsu, S., McCarron, R.M. & Spatz, M. Dopaminergic receptors linked to adenylate cyclase in human cerebromicrovascular endothelium. J. Neurochem. 57, 1774-1780 (1991).
16. Brown, L. et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. in Regulation of Angiogenesis (eds. Goldberg, I. & Rosen, E.) (Birkhauser, Basel, Switzerland, 1997).
17. Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F. & Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97-132 (1999).
18. Nagy, J. et al. Pathogenesis of ascites tumor growth: angiogenesis, vascular remodeling and stroma formation in the peritoneal lining. Cancer Res. 55, 376-385 (1995).
19. Nagy, J.A., Meyers, M.S., Masse, E.M., Herzberg, K.T. & Dvorak, H.F. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res. 55, 369-375 (1995).
20. Nagy, J.A. et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability and ascites fluid accumulation. Cancer Res. 55, 360-368 (1995).
21. Zaroslinski, J.F. et al. The pharmacology and subacute toxicology of dopamine. Proc. R. Soc. Med. 70, 2-6 (1977).
22. Dvorak, H.F. et al. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122, 166-174 (1979).
23. Senger, D.R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985 (1983).
24. Murohara, T. et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97, 99-107 (1998).
25. Pettersson, A. et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab. Invest. 80, 99-115 (2000).
26. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Curr. Top. Microbiol. Immunol. 237, 1-30 (1999).
27. Ewing, A.G., Bigelow, J.C. & Wightman, R.M. Direct in vivo monitoring of dopamine released from two striatal compartments in the rat. Science 221, 169-171 (1983).
28. Heeg, K., Reimann, J., Kabelitz, D., Hardt, C. & Wagner, H. A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J. Immunol. Methods 77, 237-246 (1985).
29. Turner, H.E. et al. Angiogenesis in pituitary adenomas-relationship to endocrine function, treatment and outcome. J. Endocrinol. 165, 475-481 (2000).
30. Takechi, A. Effect of angiogenesis inhibitor TNP-470 on vascular formation in pituitary tumors induced by estrogen in rats. Neurol. Med. Chir. 34, 729-733 (1994).
31. Nagai, Y. et al. Plasma levels of vascular endothelial growth factor in patients with acromegaly. Horm. Metab. Res. 32, 326-329 (2000).
32. Berkman, R.A., & Oldfield, R.H. Expression of vascular permeability factor J vascular endothelial growth factor gene in central nervous system neoplasms. J. Clin. Invest. 91, 153-159 (1993).
33. Otsuka, F. et al. Quantitative analysis of growth-related factors in human pituitary adenomas. Lowered insulin-like growth factor-1 and its receptor mRNA in growth hormone-producing adenomas. Regul. Pept. 83, 31-38 (1999).
34. Heaney, A.P., Horwitz, G.A., Wang, Z., Singson, R. & Melmed, S. Early involvement of estrogen induced pituitary transforming gene and fibroblast growth expression in prolactinoma pathogenesis. Nature Med. 5, 1317-1321 (1999).
35. Ashraf, S. et al. Blood vessels in liver metastasis from both sarcoma and carcinoma lack perivascular innervation and smooth muscle cells. Clin. Exp. Metastasis. 15, 484-198 (1997).
36. Chamary, V.L., Robson, T., Loizidou, M., Boulos, P.B. & Burnstock, G. Progressive loss of perivascular nerves adjacent to colorectal cancer. Eur. J. Surg. Oncol. 26, 588-593 (2000).
37. Pereira da Silva, J.A., & Carmo-Fonseca, M. Peptide containing nerves in human synovium: immunohistochemical evidence for decreased innervation in rheumatoid arthritis. J. Rheumatol. 17, 1592-1599 (1990).
38. Miller, L.E., Justen, H.P., Scholmerich, J. & Straub, R.H. The loss of sympathetic nerve fibres in the synovial tissue of patients is accompanied by increased norepinephrine release from synovial macrophages. FASEB J. 14, 2097-2107 (2000).
39. Basu, S. & Dasgupta, P.S. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig. Dis. Sci. 44, 916-921 (1999).
40. Braunwald, E. Evolution of the management of acute myocardial infarction: a 20th century saga. Lancet 352, 1771-1774 (1998).
41. Katzung, B. (ed.) Basic and Clinical Pharmacology. (Appleton and Lange, Stamford, Connecticut, 1998).